Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orthofix Medical Inc. (NASDAQ: OFIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Orthofix is a global medical technology company focused on spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, and its filings offer detailed insight into these operations.
Orthofix uses current reports on Form 8-K to announce material events such as quarterly financial results, non-GAAP financial measure discussions, and outcomes of its annual meeting of shareholders. Recent 8-K filings describe how the company reports net sales by category, including Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics, and explain non-GAAP measures like constant currency, free cash flow, adjusted gross profit, adjusted net income (loss) and adjusted EBITDA.
Through SEC filings, Orthofix also discloses information on topics such as restructuring costs and impairments related to its M6 artificial disc product lines, merger-related costs associated with SeaSpine, and other adjustments that management excludes when evaluating underlying performance. Governance-related filings, including those covering the annual meeting, document director elections, advisory votes on executive compensation, auditor ratification and board committee appointments.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand segment reporting, non-GAAP adjustments, capital structure details and governance decisions. Users can monitor new 8-Ks and other forms as they are posted to EDGAR, and use the summaries to navigate Orthofix’s financial and regulatory history more efficiently.
Orthofix Medical Inc Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the class for Orthofix common stock following an internal realignment. The filing cites an internal reorganization effective January 12, 2026 and is signed on 03/27/2026.
Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, reported an open-market sale of 4,269 shares of common stock at $11.92 per share. According to the disclosure, the sale was executed solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-approved sell-to-cover arrangement.
The transaction was carried out without any exercise of discretion by Vitale. Following this tax-related sale, he holds 160,449 shares of Orthofix common stock, which includes 127,256 previously reported restricted stock units.
Orthofix Medical Inc. director Vickie L. Capps bought a total of 5,000 shares of common stock in open-market transactions. The purchases occurred on March 9–10, 2026 at prices around $12.44–$12.48 per share. Following these trades, she directly holds 27,585 shares, which include 21,934 previously reported deferred stock units and 651 shares acquired under Orthofix's stock purchase plan.
Orthofix Medical CFO Julie Andrews reported automatic share sales related to equity compensation. On March 4 and 5, 2026, she sold a total of 4,788 shares of Orthofix Medical common stock in open‑market transactions at weighted average prices of $12.9163 and $12.5508 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations in connection with the settlement of restricted stock units under a pre‑existing, mandated sell‑to‑cover arrangement approved by the Board’s Compensation and Talent Development Committee, and were executed without her discretion. After these transactions, she directly holds 88,746 shares, including 69,552 restricted stock units.
Orthofix Medical Inc. executive Lucas Vitale, listed as CP&BOO, reported selling a total of 2,312 shares of common stock in two open-market transactions on March 4 and March 5, 2026. The shares were sold at weighted average prices of $12.9163 and $12.5508 per share.
According to a footnote, these sales were made solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, committee-mandated sell-to-cover requirement, with no discretion exercised by Vitale. After these transactions, he held 164,718 shares and restricted stock units.
Orthofix Medical Inc. President & CEO Massimo Calafiore reported automatic sales of common stock tied to tax withholding on restricted stock units. On March 4, he sold 6,189 shares at a weighted average price of $12.9163, and on March 5, he sold 6,031 shares at a weighted average price of $12.5508, for a total of 12,220 shares.
The filing explains these shares were sold under a pre-existing sell-to-cover requirement to satisfy tax obligations when restricted stock units settled, and the sales were made without any exercise of discretion by him. After these transactions, he directly holds 320,136 shares of Orthofix common stock, including 221,042 restricted stock units.
Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported selling 1,536 shares of common stock in open-market transactions on March 4 and 5, 2026 at weighted average prices of $12.9163 and $12.5508 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations under a pre-existing sell-to-cover requirement approved by a board committee and were executed without his discretionary choice. After these transactions, he held 50,633 shares and restricted stock units in total, including 41,134 previously reported restricted stock units.
Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, reported selling a total of 2,559 shares of common stock in open-market transactions on March 4 and 5, 2026.
According to the disclosure, these sales were executed to satisfy tax withholding obligations related to the settlement of restricted stock units under a pre-approved, mandatory sell-to-cover program established by the Board’s Compensation and Talent Development Committee, and were carried out without any discretionary trading decision by the reporting person. After these transactions, McPherron directly owns 67,853 shares of Orthofix common stock, which includes 54,692 previously reported restricted stock units.
Orthofix Medical Inc. President, Global Spine, Max Reinhardt reported selling 2,133 shares of common stock in open-market transactions on March 4 and March 5, 2026. The shares were sold solely to satisfy tax withholding obligations from restricted stock unit settlement under a pre-approved sell-to-cover mandate, with no discretion exercised by him. After these sales, he directly held 25,348 shares, including 19,417 restricted stock units.
Orthofix Medical Inc. chief legal officer Jorge Andres Cedron reported automatic sales of common stock to cover tax withholding on recently settled restricted stock units. A total of 2,775 shares were sold in open‑market transactions on March 4–5 under a pre-existing, committee‑mandated sell-to-cover requirement.
The shares were sold at weighted-average prices of $12.9163 and $12.5508 per share across multiple trades within specified ranges, with no discretion exercised by Cedron. Following these transactions, he beneficially owns 62,749 shares of Orthofix common stock, including 53,902 previously reported restricted stock units.